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Epidermolysis bullosa acquisita (EBA) is an acquired
bullous disease of the skin characterized by IgG auto-
antibodies against type VII (anchoring fibril) colla-
gen. We previously defined four immunodominant
antigenic epitopes within the noncollagenous 1 (NC1)
domain of type VII collagen. In this study, we pro-
duced an additional recombinant fusion protein from
the NC1 domain corresponding to the N-terminal 227
amino acids (residues 1 to 227), which contains ho-
mology with cartilage matrix protein (CMP). Using
enzyme-linked immunosorbent assay and immuno-
blot analysis, we tested sera from EBA patients (n 
32), bullous systemic lupus erythematosus patients
(n  3), bullous pemphigoid patients (n  15), and
normal humans (n  12). Twenty-six of 32 EBA sera
and two of three bullous systemic lupus erythemato-
sus sera reacted with the CMP domain, whereas none
of the control sera did. Affinity-purified anti-CMP EBA
antibodies injected into hairless mice produced the
clinical, histological, immunological, and ultrastruc-
tural features of EBA. F(ab)2 fragments generated
from anti-CMP EBA autoantibodies did not induce
disease. Our studies provide the first evidence that
EBA autoantibodies to the CMP subdomain of NC1
are pathogenic and induce blister formation. This is
the first antigenic epitope on type VII collagen
demonstrated to be a pathogenic target for EBA
autoantibodies. (Am J Pathol 2007, 170:2009–2018; DOI:
10.2353/ajpath.2007.061212)
Epidermolysis bullosa acquisita (EBA) is a severe,
chronic, subepidermal bullous disease of the skin and
mucosa characterized by skin fragility, blisters in trauma-
prone sites, scarring with milia formation, and nail dys-
trophy.1 It is a prototypic autoimmune disease in which
EBA patients have in vivo tissue-bound and circulating
IgG autoantibodies directed against type VII collagen, a
major component of anchoring fibrils, structures that an-
chor the epidermis onto the dermis.2–8 EBA autoantibod-
ies bind to type VII collagen within anchoring fibrils. EBA
patients have a diminution of normal anchoring fibrils and
subsequent epidermal-dermal disadherence. The clinical
appearance of EBA patients and the histology of their
cutaneous lesions are often very reminiscent of heredi-
tary dystrophic epidermolysis bullosa. These two dis-
eases are etiologically unrelated but share the common
feature of decreased anchoring fibrils. In the case of
inherited dystrophic epidermolysis bullosa, the cause of
decreased or absent anchoring fibrils is a genetic defect
in the gene that encodes for type VII collagen.9,10
Type VII collagen is composed of three identical 
chains, each consisting of a 145-kd central collagenous
triple-helical segment characterized by repeating Gly-
X-Y amino acid sequences, flanked by a large 145-kd
amino-terminal noncollagenous domain (NC1), and a
small 34-kd carboxyl-terminal noncollagenous domain
(NC2).6–8,11,12 Within the extracellular space, type VII
collagen molecules form anti-parallel, tail-to-tail dimers
stabilized by disulfide bonding through a small carboxyl-
terminal NC2 overlap between two type VII collagen mol-
ecules. The anti-parallel dimers then aggregate laterally
to form anchoring fibrils with large globular NC1 domains
at both ends of the structure. Sequence analysis of the
NC1 domain revealed multiple submodules with homol-
ogy to adhesive proteins.13 These include a segment with
homology to CMP, nine consecutive fibronectin type III-
like repeats (FNIII), and a segment with homology to the
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A domain of von Willebrand factor (VWF-A) (Figure 1A).
We and others have shown that NC1 interacts with vari-
ous extracellular matrix components including fibronec-
tin, laminin-5, type I collagen, and type IV collagen.14–17
Therefore, the NC1 domain may facilitate binding of type
VII collagen to other basement membrane zone (BMZ)
and matrix components. These matrix interactions are
thought to stabilize the adhesion of the BMZ to the un-
derlying dermis.
Using a panel of recombinant fusion proteins or frag-
ments of type VII collagen, we and others have shown
previously that EBA autoantibodies recognize four major
antigenic epitopes confined to the FNIII and VWF-A sub-
domains of NC1.18–20 At that time, the amino terminus of
NC1 had not been cloned or characterized. Moreover,
none of the EBA autoantibodies to the identified antigenic
epitopes was shown to be pathogenic.
The pathogenicity of rabbit anti-type VII collagen anti-
bodies in the induction of EBA has been established in
animal models by passively transferring immune rabbit
antibodies against type VII collagen into hairless
mice.21,22 Recently, we immunized rabbits and raised a
high titer antiserum to the NC1 domain of human type VII
collagen. We injected the antibody into hairless immuno-
competent mice, and the mice developed a bullous erup-
tion that had many of the features of EBA patients.21
Another recent study by Sitaru and colleagues22 showed
that the injection of rabbit polyclonal antibodies to the
NC1 domain of mouse type VII collagen into adult mice
also induced subepidermal skin blisters reminiscent of
human EBA. More recently, we affinity-purified anti-NC1
autoantibodies from EBA patients’ sera and injected them
into hairless mice. The animals developed a subepider-
mal bullous disease with clinical, histological, immuno-
logical, and ultrastructural features similar to human
EBA.23 These results provide evidence that human EBA
autoantibodies to the NC1 domain of type VII collagen
are pathogenic and capable of inducing epidermal-der-
mal separation of skin.
In this study, an additional recombinant fusion protein
corresponding to the N-terminal 227 amino acids (resi-
dues 1 to 227) of NC1 and homologous to CMP was
generated and analyzed by immunoblot and enzyme-
linked immunosorbent assay (ELISA) for reactivity with
autoantibodies from 32 EBA patients. We found that 26 of
32 EBA sera and two of three bullous systemic lupus
erythematosus (BSLE) sera reacted with the CMP domain
in both assays. We then affinity-purified anti-CMP auto-
antibodies from the serum of one EBA patient and in-
jected them intradermally into adult immunocompetent
hairless mice. The injected autoantibodies consistently
induced a subepidermal blistering disease resembling
the clinical, histological, and immunological features of
human EBA. These results demonstrate that EBA auto-
antibodies to the CMP subdomain of type VII collagen are
pathogenic and likely play an important role in the induc-
tion of epidermal dermal disadherence featured in EBA.
Materials and Methods
Patients and Sera
Serum samples were collected from 32 patients with
EBA. These EBA patients had 1) an active, chronic,
mechanobullous disorder; 2) subepidermal blisters as
assessed by routine light microscopy of lesional skin; 3)
IgG deposits detected at the dermal-epidermal junction
(DEJ) by routine direct immunofluorescence (DIF); 4) IgG
deposits localized to the dermal floor of the patient’s skin
when the DEJ was fractured through the lamina lucida by
treatment with 1 mol/L NaCl24,25; 5) immunoreactivity to
the NC1 domain of type VII collagen by ELISA and im-
munoblot analysis26; and 6) IgG deposits detected within
the sublamina densa region of the DEJ using direct im-
munoelectron microscopy.27
Because sera from patients with BSLE have been
shown to have autoantibodies to type VII collagen,28
three sera from BSLE patients were also tested. Control
serum samples were collected from 12 normal individuals
(normal human sera, NHS) and 15 patients who had
clinical, histological, and immunofluorescence findings
consistent with the diagnosis of BP. Patient and normal
control sera were stored frozen at 20°C before analysis.
Plasma was collected from one patient with EBA dur-
ing the early phase of their disease (before treatment).
This patient was plasmaphoresed for therapeutic pur-
poses, which generated large volumes of plasma rich in
anti-CMP antibodies. This EBA patient met the EBA cri-
teria outlined above. In addition, she had both IgG and
C3 deposits detected at the DEJ by routine DIF and
indirect immunofluorescence (IIF) titers ranging from
1:1280 to 1:5120 as analyzed on salt-split normal human
skin substrate. The study was conducted according to
Declaration of Helsinki Principles.
Construction and Expression of Recombinant
Fusion Proteins Corresponding to NC1
Subdomains
The fragment corresponding to the 700-bp CMP subdo-
main of human type VII collagen cDNA was generated by
Figure 1. Domain organization, four immunodominant epitopes for EBA
autoantibodies within the NC1 domain of human type VII collagen, and
expression of recombinant CMP. A: The deduced 1253-amino acid sequence
of the NC1 domain revealed motifs with homology to known adhesive
proteins. CMP, cartilage matrix protein; FNIII 1–9, nine fibronectin type
III-like repeats; VWF-A, the A domain of von Willebrand factor. Bottom
shows the four previously identified immunodominant epitopes recognized
by EBA sera. B: Ten percent SDS-PAGE and Coomassie Blue staining of
recombinant GST-CMP protein purified from bacteria. The positions of the
50-kd molecular weight marker and the GST-CMP fusion protein are
indicated.
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reverse transcriptase-polymerase chain reaction amplifi-
cation using human amniotic epithelial cell (WISH) cDNA
as a template as described previously.14 The insert was
then subcloned into a TA vector and pGEX expression
vector (Pharmacia, Inc., Piscataway, NJ), as modified by
Dr. George Giudice, Medical College of Wisconsin, Mil-
waukee, WI.29 The correct ligation and in-frame insertion
of the DNA fragment was confirmed by DNA sequence
analysis. Bacterial fusion proteins corresponding to dis-
crete segments within the NC1 domain of type VII colla-
gen were developed and purified by a glutathione-
Sepharose 4B column (Pharmacia, Uppsala, Sweden) as
described.18 These fusion proteins included CMP (resi-
dues 1 to 227), FP1 (residues 201 to 602), FP3 (residues
595 to 826), FP7 (residues 814 to 1028), and FP8 (resi-
dues 1022 to 1253).
ELISA Using CMP
Ninety-six-well microtiter plates (Immulon-4; Dynatch
Laboratory Inc., Alexandria, VA) were coated with puri-
fied glutathione S-transferase (GST)-CMP at a concen-
tration of 1.5 g/ml (0.15 g/well) in 20 mmol/L carbonate
buffer, pH 9.3, overnight at 4°C. ELISA was performed as
previously described.26 The patients’ sera dilutions
ranged from 1:100 to 1:1250.
Immunoblotting of Recombinant
Fusion Protein CMP
Purified GST-CMP protein (100 ng/well) was run on a 10%
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gel and then electrotransferred to a ni-
trocellulose membrane. Cut strips of nitrocellulose were
blocked for 60 minutes at room temperature with 10%
nonfat dry milk or overnight at 4°C with 5% bovine serum
albumin in 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl,
and 0.1% Tween 20 (TTBS). After washing with TTBS
buffer, the strips were incubated for 1 hour at room tem-
perature with individual patient sera or control sera di-
luted in TTBS with 1% bovine serum albumin (1:100). The
strips were then washed as before with TTBS three times.
The immunoreactivity was detected with a horseradish
peroxidase-conjugated goat anti-human IgG (Organon
Teknika-Cappel, Durham, NC) diluted in TTBS with 1%
bovine serum albumin (1:5000) for 30 minutes at room
temperature and enhanced chemiluminescence (Amer-
sham, Buckinghamshire, UK).
Mice
SKH1 mice were obtained from Jackson Laboratories
(Bar Harbor, ME) and hosted at the University of Southern
California Facility. These are hairless mice with an intact
immune system. Four- to 10-week-old animals were in-
jected with affinity-purified anti-CMP antibodies or flow-
through IgG (depleted of reactivity to CMP) from the EBA
patients’ sera or control IgG fractions from the sera of
normal human patients at the same IgG concentrations.
All animal studies were conducted using protocols ap-
proved by the University of Southern California Institu-
tional Animal Use Committee.
Preparation and Characterization
of IgG Fractions
The patient’s plasma was first diluted with antibody bind-
ing buffer (20 mmol/L sodium phosphate, pH 7.0) at a 1:5
dilution and then centrifuged at 4000 rpm to remove
insoluble particulate material. The supernatants were
then subjected to chromatography using a protein G-
Sepharose Fast Flow column following the manufactur-
er’s recommendation (Amersham Biosciences, Uppsala,
Sweden). Control IgG fractions were prepared in an iden-
tical manner from a commercial lot of human gamma
globulins obtained from several hundred normal donors
(Sigma, St. Louis, MO). IgG fractions from the EBA pa-
tient were further affinity-purified using recombinant GST-
CMP fusion protein covalently coupled to a CNBr-acti-
vated Sepharose 4B column following the manufacturer’s
instructions (Amersham Biosciences). Affinity-purified
anti-CMP EBA antibodies were dialyzed against phos-
phate-buffered saline, concentrated by Centricon
Plus-20 ultrafiltration (Amicon, Lexington, MA) to 20 to 50
mg/ml, filter-sterilized, and stored at 20°C. By IIF, anti-
body titers ranged from 1:5000 to 1:10,000 on normal
human skin, mouse skin, and salt-split skin substrate. The
affinity-purified autoantibodies were also assessed by
Western blot analyses and ELISA as described.26
Preparation of F(ab)2 Fragments
F(ab)2 fragments of affinity-purified anti-CMP IgG were
prepared by digestion with pepsin as described.23 Un-
digested IgG and Fc fragments were removed by affinity
chromatography using a protein G-Sepharose Fast Flow
column (Amersham Biosciences). Purified F(ab)2 frag-
ments migrated as a 100-kd band under nonreduced
SDS-PAGE. The completeness of digestion was as-
sessed by IIF on mouse skin substrate. The purified
F(ab)2 preparations showed reactivity only with a fluo-
rescein isothiocyanate (FITC)-labeled goat anti-human-
F(ab)2 but not with a FITC-labeled goat anti-human-Fc
secondary antibodies.
Administration of EBA Antibodies, Animal
Evaluation, and Characterization
SKHl mice were injected intradermally with EBA anti-CMP
IgG (n  8), EBA IgG depleted of reactivity to the CMP
domain of NC1 (flow-through fractions from the CMP
affinity column) (n  7), or normal human control IgG (n 
8) once every day for 8 days and observed every day.
IgG doses ranged from 10 to 400 g/g body weight/per
day. The animals were photographed daily. Skin ery-
thema, blisters, and erosions were recorded. Mice that
developed blisters had skin biopsies from the blisters
and nonblistered normal-appearing skin within 0.5 cm of
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a blister. Skin samples were fixed in 10% buffered forma-
lin and stained with hematoxylin and eosin. Both lesional
and perilesional tissues were subjected to DIF staining as
previously described.2,24 Monospecific FITC-conjugated
sera were obtained commercially: goat anti-human IgG
(Sigma), monospecific goat anti-mouse C3 (Cappel Lab-
oratories, Durham, NC), goat anti-mouse neutrophils (Ce-
darlane, Ontario, ON, Canada), and goat anti-human
F(ab)2 and Fc (Cappel Laboratories). Photographs of
immunolabeled tissues were obtained with a Zeiss Axio-
plan fluorescence microscope equipped with a Zeiss
Axiocam MRM digital camera system (Carl Zeiss, Thorn-
wood, NY).
Results
CMP of NC1 Domain Harbors Epitopes
Recognized by EBA Autoantibodies
We previously produced a series of GST fusion pro-
teins encompassing the complete FNIII and VWFA re-
gions of NC1 domain (Figure 1).18 In this study, we
produced an additional NC1 subdomain recombinant
fusion protein corresponding to the N-terminal 227
amino acids (residues 1 to 227) of NC1 and homolo-
gous to CMP. These recombinant type VII collagen
fusion proteins were used to identify regions within
NC1 recognized by EBA sera. As shown previously,
EBA autoantibodies recognize four major NC1 anti-
genic epitopes confined within FINIII and VWF-A sub-
domains of NC1 (Figure 1A).18 By ELISA, 26 of 32 EBA
sera (81%) exhibited reactivity with CMP with optical
density (OD) values ranging from 0.4 to 2 (Figure 2).
Two of three BSLE sera also reacted with CMP, con-
sistent with previous studies showing that BSLE sera
contain autoantibodies to NC1.28 In contrast, all control
sera (15 BP and 12 NHS) showed background reactiv-
ity with CMP with values less than 0.21 OD (0.25 OD is
the cutoff for a positive ELISA reading).26
The 26 EBA and 2 BSLE sera that reacted with CMP in
the ELISA were further analyzed by immunoblot analysis.
A representative blot is shown in Figure 3. The 50-kd
GST-CMP fusion protein was recognized by 22 EBA sera
and two BSLE sera but not by BP or normal human sera
at the same 1:100 dilution. Four EBA sera were negative
by immunoblot analysis even when the serum dilution
was decreased to 1:20. These four EBA sera are those
sera with the lowest reactivity to CMP by ELISA. Taken
together, these data show that like FINIII and VWF-A
subdomains, CMP also contains epitopes recognized by
the majority of EBA autoantibodies.
Epitopes within CMP Are Recognized by
Pathogenic EBA Autoantibodies
We recently showed that affinity-purified autoantibod-
ies against type VII collagen NC1 from EBA patients’
sera induced subepidermal blisters when injected into
adult hairless immunocompetent mice.23 To determine
whether pathogenic EBA autoantibodies are reactive
with CMP epitopes, we affinity-purified CMP-specific
EBA antibodies and analyzed these antibodies by im-
munoblotting and immunofluorescence. Using a panel
of GST fusion proteins encompassing the complete
NC1 domain of type VII collagen (Figure 4A),18 we
found that the pathogenic EBA IgG used in this study
recognized exclusively only CMP (Figure 4B, lane 2).
The antibody reactivity with this antigenic epitope was
specific because the EBA IgG did not recognize FP1,
FP3, FP7, or FP8 (Figure 4B, lanes 3 to 6). Further,
control normal human serum did not react with any of
these fusion proteins (data not shown). As expected,
the CMP-specific EBA antibodies only reacted with the
50-kd CMP protein and NC1, not with other fusion
proteins (Figure 4C.). These data indicate that
epitopes recognized by pathogenic EBA IgG reside
within the first 227 AA of NC1.
To determine whether EBA-IgG also reacts with mu-
rine type VII collagen, we performed an immunoblot
using type VII collagen extracted from murine skin. As
Figure 2. Scatter plot representation of ELISA results using recombinant
CMP. Patient and control sera (as indicated along the horizontal axis) (1:200
dilution) were incubated with immobilized CMP subdomain, and the bound
antibodies detected with an alkaline phosphatase-conjugated antibody
against human IgG. Each sample was run in triplicate. The points plotted on
this graph are the average of the OD405 obtained from study sera. Similar
results were obtained in three other independent experiments.
Figure 3. Immunoblot of the recombinant GST-CMP proteins by EBA and
control sera. Purified recombinant GST-CMP (100 ng/well) protein was
separated on 10% SDS-PAGE and transferred to nitrocellulose membranes
before incubation with sera at a dilution of 1:100 and horseradish peroxidase-
conjugated anti-human IgG (1:5000) followed by enhanced chemilumines-
cence detection. Lane 1, NHS; lane 2, BP; lanes 3 to 12, EBA; and lanes 13
to 14, BSLE. The positions of the 50-kd molecular weight marker and the
GST-CMP fusion protein are indicated.
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shown in Figure 4D, EBA-IgG, but not control normal
human sera, specifically recognized the murine 290-kd
type VII collagen  chain. Because pathogenic EBA
autoantibodies bind to type VII collagen in skin, we
determined whether the purified anti-CMP EBA anti-
bodies reacted with skin by IIF. As shown in Figure 4E,
the anti-CMP antibodies strongly stained the BMZ of
both human and mouse skin at dilution titers of more
than 1:10,000. The control IgG fraction purified from
normal human sera did not label either mouse or hu-
man skin (data not shown). In addition, like pathogenic
EBA autoantibodies, the anti-CMP antibody labeled the
dermal side of salt-split human skin (Figure 4EC). Fi-
nally, EBA IgG depleted of reactivity to the CMP sub-
domain (flow-through fractions from CMP affinity col-
umn) did not stain mouse skin (Figure 4ED).
Mice Injected with Anti-CMP Antibodies
Develop EBA
To test whether anti-CMP autoantibodies are pathogenic,
we intradermally injected SKH1 mice with affinity-purified
anti-CMP antibodies daily at a dose of 50 g/g body
weight per day. The characteristics of the anti-CMP EBA
antibodies are outlined in Table 1. As shown in Figure 5,
animals injected with anti-CMP EBA antibodies (n  8)
showed blisters as early as 8 days after the initial injection
(Figure 5, A and C). With time, these blisters ruptured and
additional erosions, crusted lesions, and blisters were
observed on the body nearby the injection area, as well
as the ears in some mice (Figure 5, B, D, and E). Four of
eight (50%) injected mice lost their nails (Figure 5, F). As
Figure 4. Epitope mapping of anti-type VII collagen EBA antibodies. A: Schematic diagram of the recombinant fusion proteins encompassing the complete NC1
domain of type VII collagen. Four deletion mutant recombinant proteins along with CMP are shown in the schematic with the amino acid residue numbers
indicated. B and C: Purified recombinant NC1, as well as five other recombinant fusion proteins (400 ng/well) were separated on a 10% SDS-PAGE gel and
transferred to nitrocellulose membranes. The transferred proteins were incubated with EBA antibodies before (B) and after (C) affinity purification at a dilution
of 1:100 and horseradish peroxidase-conjugated anti-human IgG (1:5000) followed by enhanced chemiluminescence detection. Lanes 1, 2, 3, 4, 5, and 6 are NC1,
CMP, FP1, FP3, FP7, and FP8, respectively. The locations of the 145-kd recombinant NC1, CMP, and molecular weight markers are indicated. D: Protein extracts
from mouse skin were separated on 6% SDS-PAGE and immunoblotted with affinity-purified anti-CMP antibodies (EBA) or normal human sera (NHS) at a dilution
of 1:100. Please note that a polypeptide of 290-kd murine type VII collagen  chain was recognized by EBA autoantibodies only. The locations of the 290-kd
mouse type VII collagen and molecular weight markers are indicated. E: Immunolabeling of mouse and human skin with the affinity-purified anti-CMP EBA
antibodies. Immunofluorescence staining was performed on human skin (A), mouse skin (B, D), and salt-split human skin (C). The tissue was labeled with EBA
antibodies diluted 1:1000 and a FITC-conjugated goat anti-human IgG. Note that the affinity-purified anti-CMP EBA antibodies strongly labeled the BMZ of both
mouse and human skin (D) and the dermal floor of salt split human skin (A–C). In contrast, flow-through IgG depleted of reactivity to CMP did not stain the BMZ
of the mouse skin. d, dermis; e, epidermis. Scale bar, 200 m.
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summarized in Table 1, cutaneous lesions occurred in all
eight experimental mice given anti-CMP EBA antibodies.
In contrast, none of the eight animals injected with iden-
tical or higher doses of control IgG developed any cuta-
neous lesions. Furthermore, none of the seven animals
injected with EBA IgG depleted of reactivity to the CMP
subdomain of NC1 (flow-through fractions from CMP af-
finity column) developed skin lesions. Two experimental
mice exhibited weight loss after the 8-day injection pe-
riod. We sacrificed these mice and performed histology
of various organs. We observed erosions in the oral mu-
cosa and the upper one-third of the esophagus (data not
shown). Many, but not all, patients with EBA have involve-
ment of the oral mucosa and upper one-third of the
esophagus.
Histological examination of lesional skin of the diseased
mice showed an EBA-like DEJ separation (Figure 6Aa).
There was also a moderate dermal inflammatory infiltrate
consisting mostly of mononuclear cells and a few neutro-
phils. In contrast, mice injected with similar concentrations
of control normal human IgG had a normal epidermis and
dermis without any pathological alteration (Figure 6Ab). Fur-
ther, injection of flow-through IgG into mice did not show
any disease pathology (data not shown).
DIF of perilesional and lesional skin demonstrated
that all of the mice injected with anti-CMP EBA anti-
bodies had human IgG deposits along the BMZ (Figure
6B). Human anti-CMP IgG deposits were also detected
in the ear, oral mucosal, and esophagus of the injected
mice. In contrast, all seven mice that received EBA IgG
depleted of reactivity to the CMP subdomain did not
show any deposits of human IgG, along the BMZ in
skin.
In addition to deposits of human IgG, in six of eight
experimental mice, continuous deposits of murine C3
complement were also observed at the BMZ (Figure
6C). Neutrophils were detected within the dermal in-
flammatory infiltrate (Figure 6C). In contrast, there were
no murine C3 deposits at the BMZ or neutrophils in the
dermis of the mice receiving equivalent amounts of
Table 1. Characterization of the Affinity-Purified Anti-CMP
EBA Antibodies Used and the Incidence of
Disease in Injected Mice









EBA patient 10,000 10 to 50 8/8
Control IgG‡ 0 20 to 400 0/8
Flow-through IgG§ 0 20 to 400 0/7
*Titers of concentrated affinity-purified anti-CMP EBA antibodies
tested against normal mouse skin.
†The numerator denotes the number of mice in which skin lesions
developed; the denominator denotes the total number of mice that
received injections.
‡Normal human serum.
§Flow-through IgG from the flow-through fractions of the CMP affinity
column in which the reactivity to CMP subdomain was depleted.
Figure 5. Clinical appearance of SKH1 mice injected with anti-CMP EBA antibodies. A–F: SKH1 mice were injected intradermally with EBA antibodies at 50 g/g
body weight once every day for 8 consecutive days. Eight to 12 days after the injections were started, animals developed numerous blisters, erosions, and crusts
forming from ruptured blisters (A and B, days 8 and 12 after eight injections; C and D, days 8 and 13 after eight injections). E: Lesions were observed on the
animals’ ears at 14 days after the initial injections (eight injections). F: Nail loss was also observed in some mice.
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control normal human IgG (control IgG) or flow-through
IgG depleted of reactivity to the CMP subdomain
(FT-IgG).
F(ab)2 Fragments of Anti-CMP Antibodies Do
Not Induce Blisters
To determine whether complement activation was re-
quired for the induction of blisters and nail loss in the
mice injected with anti-CMP antibodies, we prepared
F(ab)2 fragments of the affinity-purified anti-CMP an-
tibodies by removing the complement-binding, ie, Fc
domains, of the antibodies. We injected F(ab)2 frag-
ments into SKH1 mice using equimolar doses as intact
anti-CMP IgG. In contrast to the experiments with com-
plete anti-CMP IgG, the skin of mice injected with
F(ab)2 did not develop clinical blisters or any lesions
(Figure 7A). When the DIF analysis was performed in
Figure 6. Histological and immunological ex-
amination of lesional skin of SKH1 mice injected
with anti-CMP EBA antibodies. A: Histological
appearance of skin lesions induced by EBA au-
toantibodies. H&E staining of lesional murine
skin (a) showed separation of the epidermis (e)
from the dermis (d). No epidermal-dermal sep-
aration was detected in mice receiving equiva-
lent amounts of normal human control IgG (b).
B: Immunofluorescence analysis of SKH1 mice
injected with anti-CMP EBA antibodies. Cryosec-
tions of perilesional and lesional skin as well as
other organs were labeled with FITC-conjugated
goat anti-human IgG. Note the mice injected
with anti-CMP EBA antibodies had in situ depos-
its of human IgG at the BMZ of perilesional and
lesional skin (A and B), perilesional and lesional
ear lesions (C and D), esophagus (E and F), and
oral mucosal (G). In contrast, mice receiving
equivalent amounts of flow-through IgG de-
pleted of reactivity to CMP (H) or purified con-
trol normal human IgG (I) had no deposits of
human IgG. C: Immunofluorescence analysis
was performed with FITC-conjugated goat anti-
mouse C3 antibody (-mC3) and FITC-conju-
gated goat anti-mouse neutrophil antibody (-
PMN). Note linear deposits of murine C3 at the
BMZ of perilesional and lesional skin in mice
injected with anti-CMP EBA antibodies. Please
also note neutrophils in the dermis. In contrast,
in mice receiving equivalent amounts of purified
control normal human IgG (control IgG) or
flow-through IgG depleted of reactivity to CMP
(FT-IgG), no murine C3 deposits or neutrophils
were detected.
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the skin of the injected mice, the skin exhibited F(ab)2
at the DEJ but no human IgG Fc or murine complement
C3 (Figure 7, B–D). As expected, F(ab)2 fragments
prepared in an identical manner from control human
IgG and injected into the mice did not induce lesions
(data not shown).
Discussion
In this study, we demonstrate that the majority of autoan-
tibodies from EBA patients recognize the CMP subdo-
main of type VII collagen. Twenty-six of 32 EBA sera and
two of three BSLE sera were reactive with CMP. More
importantly, anti-CMP antibodies from EBA serum, when
passively transferred into hairless, immunocompetent
mice, induced a subepidermal bullous disease similar to
EBA. Like many EBA patients, the diseased mice often
had loss of nails and mucosal involvement. In addition,
like EBA patients, these mice had tissue-bound IgG de-
posits at the BMZ of their skin, mouth, and esophagus.
Taken together, the mice injected with anti-CMP EBA
antibodies exhibited clinical, histological, and immuno-
logical features akin to patients with EBA.
Mice injected with anti-CMP EBA antibodies also ex-
hibited very similar features to the mice in our previous
passive transfer studies using human anti-EBA autoanti-
bodies purified from an NC1 affinity column. The only
difference is that the amount of anti-CMP EBA antibodies
used to induce the disease (10 to 50 g/g body weight
per day) was approximately half the amount needed in
our previous studies (20 to 100 g/g body weight per
day). It is likely that pathogenic anti-type VII collagen
antibodies are highly enriched by affinity purification on a
CMP affinity column. The fact that affinity-purified human
EBA sera against CMP could produce the full-blown man-
ifestations of EBA in animals suggests that one of the
main pathogenic epitopes of type VII collagen resides
within the CMP subdomain.
Our conclusion that CMP harbors a major pathogenic
epitope is further confirmed by the finding that EBA IgG
antibodies depleted of activity to CMP (ie, the flow-
through fractions from the CMP affinity column) failed to
induce any lesions in the mice. Our previous epitope
mapping studies identified four distinct, independent
epitopes within the NC1 domain recognized by EBA se-
ra.18 Three of the four epitopes are clustered to the FINIII.
The fourth EBA antigenic epitope is located within the
VWF-A. However, in those studies the CMP subdomain
had not yet been cloned. Therefore, it was not available
for epitope mapping. Further, none of the EBA autoanti-
bodies to any of these four epitopes were demonstrated
to be pathogenic. In the present study, we identified CMP
as a prominent immunodominant site and demonstrated
that the CMP epitope is pathogenic, the first pathogenic
epitope identified to date. It should be mentioned that
rabbit anti-NC1 antibodies used in our previous passive
transfer studies recognized multiple epitopes including
the four previously identified epitopes plus the CMP sub-
domain (data not shown). Because we injected mice with
total anti-NC1 antibodies, we did not know in that study
which epitope(s) was responsible for the disease induc-
tion.21 Similarly, in the study reported by the Sitaru and
colleagues,22 they used a mixture of rabbit anti-mouse
type VII collagen antibodies immunized from three pep-
tides (residues 97 to 200, 479 to 587, and 757 to 967)
within the NC1 domain to induce disease in the animals.
Two of those peptides were generated using FINIII, the
previously identified antigenic epitopes for EBA patient
sera and another one consisting of half of the CMP sub-
domain (amino acid residues 97 to 200). However, which
of these antigenic epitopes was actually involved in the
disease pathogenesis was not identified because a mix-
ture of rabbit anti-mouse type VII collagen antibodies was
used for the passive transfer experiments.
It is well known that an antigenic epitope is not always
the same as a pathogenic epitope. For example, in pem-
phigus paraneoplastica, there are numerous autoanti-
bodies to plakin proteins (eg, desmoplakin, periplakin,
and envoplakin) that are markers of the disease but do
not cause skin bullae. That is, they are antigenic marker
autoantibodies but not pathogenic. The significance of
our present studies is underscored by that fact that our
patient sera exclusively recognized only the CMP subdo-
main of type VII collagen and yet could induce full-blown
EBA when passively transferred into animals. Because
six of the 32 EBA (19%) sera tested in the present study
did not react with CMP, it is likely that EBA autoantibodies
that target NC1 subdomains other than CMP may also be
pathogenic and involved in the disease development.
This possibility can be tested directly by passive transfer
experiments with affinity-purified EBA autoantibodies
against other NC1 subdomains. However, EBA is a rare
disease, and our limited availability of large quantities of
patient sera needed for this kind of study prevents us
from addressing this issue at the present time.
Figure 7. Clinical and immunological examination of SKH1 mice injected
with the F(ab)2 fragments generated from anti-CMP EBA antibodies. A:
Clinical appearance of skin injected with F(ab)2 fragments at 40 g/g body
weight once every day for 8 consecutive days showed no signs of skin
blisters. B–D: Immunofluorescence analysis of SKH1 mice skin injected with
F(ab)2 fragments of anti-CMP antibodies. Cryosections of injected skin were
labeled with FITC-conjugated goat anti-human Fab (B), goat anti-human Fc
(C), and goat anti-mouse C3 (D). Note the strong binding of F(ab)2 frag-
ments to the BMZ but the absence of Fc and murine C3 complement within
the BMZ. e, epidermis; d, dermis.
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Anchoring fibrils are reduced in the skin of EBA pa-
tients, but the underlying mechanism leading to this re-
duction is unknown.27,30 One possible mechanism is that
binding of autoantibodies to type VII collagen may target
functional epitopes on the NC1 domain and interfere with
its adhesive function. This could perturb critical direct
interactions between type VII collagen and other extra-
cellular components within the DEJ or high papillary der-
mis such as type IV collagen, laminin-5, or fibronec-
tin.14–17 In this regard, we and others have shown that
NC1 binds to laminin-5, type IV collagen, and fibronec-
tin.14–17 These interactions may be necessary for keep-
ing the DEJ intact.
Another possible mechanism for autoantibody-in-
duced blisters in EBA is that binding of EBA autoantibod-
ies to type VII collagen invokes an inflammatory cascade
that results in proteolytic degradation of matrix compo-
nents within the DEJ that are essential for dermal-epider-
mal adherence, including type VII collagen itself. In pre-
vious studies with the passive transfer EBA animal
models, we and others22,23 have shown that complement
fixation likely plays a role in the pathogenesis of the
murine EBA model. In the present study, we also showed
that affinity-purified anti-CMP EBA IgG, but not flow-
through IgG (depleted of CMP reactivity), fixed murine C3
complement and recruited neutrophils when injected into
mice. We further demonstrated that injection of mice with
pepsin-derived F(ab)2 fragments prepared from human
anti-CMP EBA antibodies did not produce clinical or his-
tological EBA lesions. These data suggest that the Fc
domains of anti-CMP EBA antibodies are needed for
subepidermal blister formation. Because antibody-spe-
cific activation of the complement system is mediated via
the Fc portion of IgG molecules, our results indicate that
anti-CMP EBA antibodies induce subepidermal blisters
and other EBA features in mice via the activation of the
complement system.
In summary, this study identifies CMP as a previously
unrecognized new antigenic epitope recognized by most
EBA patient sera. Further, we demonstrate that EBA au-
toantibodies directed against the CMP subdomain are
pathogenic when passively transferred into hairless im-
munocompetent mice. The characterization of pathogen-
ically active autoantibodies directed against the CMP
subdomain should provide valuable molecular tools to
dissect the molecular and immunological mechanisms of
subepidermal blister formation in EBA. The further fine
mapping of the pathogenic epitope to a smaller region
with the 227 AA CMP subdomain may also facilitate the
development of effective therapy for EBA such as pep-
tide therapy.
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